Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Amendment Case Law Allows FDA To Dictate Warnings – AARP

Executive Summary

First Amendment case law leaves FDA with ample authority to require specific warnings in product promotions, AARP maintains

You may also be interested in...



FDA Labeling Standards Top Kennedy’s Agenda For Commissioner Nominee

FDA will base its regulation of product labeling "on the science about how the public understands and interprets information on labels," Commissioner-nominee Mark McClellan told the Senate Health Committee Oct. 7

Rx Labeling Should Be Left To Manufacturers, Not FDA, Pfizer Says

FDA should allow manufacturers to choose the exact wording of required substantive information in their labels, 1Pfizer's comments on First Amendment issues state

FDA Seeks Comment On Ad Regs: Can Rx Be More Regulated Than OTCs?

FDA is requesting comment on the legal underpinnings for arguing that promotions of prescription drugs can be more tightly regulated than those for other products

Related Content

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel